2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN).
Euro Surveill
; 29(7)2024 Feb.
Article
en En
| MEDLINE
| ID: mdl-38362622
ABSTRACT
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95%â¯CI 51-72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95%â¯CI 33-71) than clade 5a.2a (67%; 95%â¯CI 48-80), and lowest against influenza A(H3N2) (40%; 95%â¯CI 5-61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95%â¯CI 21-65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95%â¯CI 28-85).
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Gripe Humana
/
Subtipo H1N1 del Virus de la Influenza A
/
COVID-19
Tipo de estudio:
Screening_studies
Límite:
Humans
País como asunto:
America do norte
Idioma:
En
Año:
2024
Tipo del documento:
Article